Abstract |
Breast cancer, which preferentially metastasizes to bone, is the most common malignancy among women worldwide and is a leading cause of death. Clinical data from large, phase 3 trials (ie, ABCSG-12, ZO-FAST, and AZURE) demonstrate significantly improved disease-free survival with zoledronic acid in some patient populations with early breast cancer. Although the interim results from the AZURE trial did not show a disease-free survival benefit with zoledronic acid in the overall patient population, subset analyses showed that zoledronic acid significantly improved disease-free survival in women with established postmenopausal status at baseline. Similarly, subset analyses of the ABCSG-12 trial showed greater benefits from zoledronic acid in patients over 40 years of age who theoretically would have achieved more complete ovarian suppression. Together, these data support a potential role for zoledronic acid beyond bone health in breast cancer and suggest that the endocrine environment may influence the anticancer potential of zoledronic acid.
|
Authors | Michael Gnant |
Journal | Current oncology reports
(Curr Oncol Rep)
Vol. 14
Issue 1
Pg. 35-43
(Feb 2012)
ISSN: 1534-6269 [Electronic] United States |
PMID | 22113793
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents, Hormonal
- Bone Density Conservation Agents
- Diphosphonates
- Imidazoles
- Zoledronic Acid
|
Topics |
- Antineoplastic Agents, Hormonal
(therapeutic use)
- Bone Density Conservation Agents
(therapeutic use)
- Breast Neoplasms
(drug therapy, mortality, pathology)
- Chemotherapy, Adjuvant
- Clinical Trials as Topic
- Diphosphonates
(therapeutic use)
- Disease-Free Survival
- Female
- Humans
- Imidazoles
(therapeutic use)
- Survival Rate
- Zoledronic Acid
|